CytomX Therapeutics, Inc. (CTMX) Balance Sheet
As of 2026-06-30 (10-Q), CytomX Therapeutics, Inc. (CTMX) reported total assets of $381.2M, total liabilities of $79.2M and shareholders' equity of $302.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $17.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTMXCytomX Therapeutics, Inc.Follow CTMX — free
—
Price chart with a free account
- Market cap
- 505.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 59.8 | 104.6 | 177.5 | 247.6 | 188.4 | 191.9 | 205.5 | 193.7 | 17.2 | 38.1 | 12.7 | 17.2 | |
| Short-term investments | 126.9 | 77.3 | 196.6 | 188.6 | 107.7 | 124.3 | 99.7 | 0.0 | 157.3 | 62.6 | 124.4 | 313.1 | |
| Receivables | 0.4 | 2.2 | 10.1 | 0.1 | 0.0 | 0.8 | 0.8 | 36.0 | 3.4 | 3.1 | 2.0 | 37.5 | |
| Current assets | 189.8 | 188.1 | 388.6 | 445.5 | 303.3 | 324.0 | 310.3 | 237.1 | 182.9 | 107.3 | 143.9 | 373.2 | |
| Total assets | 197.2 | 199.1 | 397.6 | 457.1 | 341.3 | 358.7 | 339.4 | 260.9 | 201.8 | 120.5 | 151.6 | 381.2 | |
| Current liabilities | 15.7 | 35.8 | 61.1 | 97.9 | 85.6 | 68.1 | 77.9 | 152.6 | 155.9 | 85.8 | 46.6 | 39.9 | |
| Total liabilities | 71.1 | 120.6 | 327.7 | 326.2 | 290.2 | 366.4 | 339.9 | 346.6 | 249.2 | 121.0 | 52.6 | 79.2 | |
| Shareholders' equity | 126.1 | 78.5 | 69.9 | 135.8 | 25.5 | -7.8 | -0.5 | -85.8 | -47.4 | -0.5 | 99.0 | 302.1 |
USD millions · SEC XBRL
CytomX Therapeutics, Inc. — questions
- How much cash does CytomX Therapeutics, Inc. have?
- $17.2M in cash and cash equivalents as of 2026-06-30.
- What are CytomX Therapeutics, Inc.'s total assets?
- $381.2M as of 2026-06-30.
- What is CytomX Therapeutics, Inc.'s shareholders' equity?
- $302.1M as of 2026-06-30.
Every figure on this page comes from CytomX Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.